# Tolera Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tolera-therapeutics

- Industry: Biotechnology
- Headquarters: Kalamazoo, US
- Website: www.tolera.com
- Total disclosed funding: $18M
- Latest round: Series B (Oct 16, 2012)
- Investors on record: 3

## About

Tolera Therapeutics Inc. specializes in biopharmaceutical development, focusing on innovative therapies to enhance immune tolerance and treat autoimmune diseases.Tolera Therapeutics Inc. was founded in 2007 and is based in Kalamazoo, US. The company is dedicated to the development of therapies that aim to promote immune tolerance in autoimmune disease treatment. In September 2014, Tolera secured USD 0.25 million in VENTURE DEBT from investors including Hopen Life Science Ventures, SWMF Life Science Venture Fund, L.P., and Triathlon Medical Partners. The company has successfully completed a total of 9 deals since its inception.TolEra.com offers a premium domain name that serves as a versatile platform for brands looking to establish or enhance their online presence. The domain is positioned as a valuable asset for businesses aiming to adapt and thrive in a changing marketplace, particularly in the realms of business and strategy. The company focuses on facilitating the sale of its domain through various purchasing options, including outright purchase and structured payment plans. TolEra.com is targeted towards a diverse client base, including entrepreneurs, startups, and established companies across global markets such as North America, Europe, and Asia. The functionality of the domain is designed to meet the needs of brands seeking a catchy and pronounceable online identity that enhances their visibility and market appeal.The revenue model for TolEra.com is primarily based on the sale of domain names, specifically through direct transactions with clients. Customers can choose from a range of payment options, which include a one-time purchase price or a payment plan that allows for an initial deposit followed by monthly installments. For example, the domain is offered at a price of USD 4,239, with a payment plan option requiring an upfront payment of USD 419.66 and subsequent monthly payments of USD 184 over 23 months. This transaction structure caters to both business-to-consumer and business-to-business sales, providing flexibility for various customer financial strategies while ensuring the company capitalizes on the premium value of its domain offerings.In September 2014, Tolera Therapeutics Inc. raised USD 0.25 million in VENTURE DEBT to enhance its development programs. The company plans to leverage this funding to advance its ongoing research initiatives in immune tolerance therapies. Specific upcoming products have not been detailed, but there is an intent to explore further opportunities within the biopharmaceutical sector. Additionally, Tolera is considering expansion into new markets, particularly in Europe and Asia, to broaden its reach and impact in the autoimmune disease treatment landscape.

## Funding rounds

- Series B, Oct 16, 2012, $5.5M — Triathlon Medical Partners, Hopen Life Science Ventures, Southwest Michigan First Life Science Fund
- Series B, May 21, 2010, $4.1M — Triathlon Medical Partners, Southwest Michigan First Life Science Fund
- Series A, Jun 16, 2008, $8M — Triathlon Medical Partners, Southwest Michigan First Life Science Fund

## Investors

- Triathlon Medical Partners (https://capitalatlas.ai/funds/triathlon-medical-partners) — Series A, Series B
- Southwest Michigan First Life Science Fund (https://capitalatlas.ai/funds/southwest-michigan-first-life-science-fund) — Series A, Series B
- Hopen Life Science Ventures (https://capitalatlas.ai/funds/hopen-life-science-ventures) — Series B